Aslan to reduce headcount, operating costs to support upcoming milestones

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Tuesday it will reduce headcount by 30% and slash operating costs by 50%.

The restructuring will help support Aslan well into 2020 as it focuses operations

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE